Current State of Circulating MicroRNAs as Cancer Biomarkers

Author:

He Yuqing1,Lin Juanjuan2,Kong Danli2,Huang Mingyuan3,Xu Chengkai2,Kim Taek-Kyun4,Etheridge Alton5,Luo Yanhong2,Ding Yuanlin2,Wang Kai4

Affiliation:

1. Institute of Medical Systems Biology, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, Guangdong, China

2. Department of Epidemiology and Medical Statistics, Guangdong Medical University, Dongguan, Guangdong, China

3. Department of Health Inspection, Guangdong Medical University, Dongguan, Guangdong, China

4. Institute for Systems Biology, Seattle, WA

5. Pacific Northwest Diabetes Research Institute, Seattle, WA

Abstract

Abstract BACKGROUND Numerous studies have demonstrated the existence of stable regulatory RNAs, microRNAs (miRNAs), in the circulation and have shown that the spectrum of these extracellular miRNAs is affected by various pathologic conditions including cancers. CONTENT Circulating miRNAs have been the focus of numerous cancer biomarker discovery efforts over the past few years; however, a considerable number of these studies have yielded inconsistent and irreproducible findings. Here, we have summarized and compared the results of studies covering 8 different cancer types to address key questions, including the possibility of using circulating miRNA to detect cancers and what factors may affect miRNA signatures. Although identifying circulating miRNA signatures to detect specific types of early stage cancers can be challenging, study results suggest that it may be possible to use miRNAs to detect cancers in general. SUMMARY Circulating miRNA is a rich source for potential disease biomarkers; however, factors, both intrinsic and extrinsic, that may affect measurement of circulating miRNA have not been fully characterized. Better understanding of intra- and intercellular miRNA trafficking and the fundamental biology of cancer cell–derived lipid vesicles may facilitate the development of circulating miRNA-based biomarkers for cancer detection and classification.

Funder

National Science Foundation

International Science and Technology Center

International Science & Technology Cooperation Program of Dongguan

Guangdong Medical University Integration of Industry

Department of Education of Guangdong Province

Science & Technology Program of Dongguan

DOD

Publisher

Oxford University Press (OUP)

Subject

Biochemistry (medical),Clinical Biochemistry

Reference69 articles.

1. WHO. All cancers (excluding non-melanoma skin cancer) estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (Accessed September 2014).

2. microRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review;Iorio;EMBO Mol Med,2012

3. Extracellular microRNA: a new source of biomarkers;Etheridge;Mutat Res,2011

4. PGE2-driven expression of c-Myc and oncomir-17–92 contributes to apoptosis resistance in NSCLC;Krysan;Mol Cancer Res,2014

5. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer;Zhu;Br J Cancer,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3